Plans for e-Therapeutics' ETS2101 Phase I Trials of Cancer Approved by Regulatory Agencies

E-Therapeutics plc declares that in fact regulatory agencies in the United Kingdom as well as the United States have approved plans for phase I trials of a typical Company's anti-cancer medication ETS2101 understanding that enrolment of affected individuals into trials during these two nations will begin soon. 

A phase I trial in the UK can recruit affected individuals with a number of solid tumors, even if a US investigator-led trial will enroll affected individuals along with primary or secondary brain cancers. Further information on each trial will probably be provided whenever its first patient will be treated.

Professor Malcolm Young, CEO of e-Therapeutics, said: "We continue to be on track to describe the very first data from cancer trials by using ETS2101 and to improve three further drugs straight into the clinic by the end of the year."